Takeda Pharmaceutical (NYSE:TAK) Sets New 1-Year High – Here’s What Happened

Takeda Pharmaceutical Company Limited (NYSE:TAK)’s stock price reached a new 52-week high on Wednesday . The stock traded as high as $15.08 and last traded at $15.07, with a volume of 773113 shares changing hands. The stock had previously closed at $14.83.

Takeda Pharmaceutical Stock Up 1.5 %

The company has a fifty day moving average price of $13.47 and a 200 day moving average price of $13.89. The company has a market cap of $47.90 billion, a PE ratio of 37.64, a price-to-earnings-growth ratio of 0.24 and a beta of 0.46. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.31 and a quick ratio of 0.72.

Takeda Pharmaceutical (NYSE:TAK) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.42 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. As a group, analysts anticipate that Takeda Pharmaceutical Company Limited will post 1.64 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Versant Capital Management Inc purchased a new position in Takeda Pharmaceutical in the 4th quarter worth about $26,000. Wilmington Savings Fund Society FSB bought a new stake in Takeda Pharmaceutical in the 3rd quarter worth approximately $40,000. BNP Paribas Financial Markets raised its stake in Takeda Pharmaceutical by 416.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock valued at $46,000 after buying an additional 2,596 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Takeda Pharmaceutical by 123.6% during the 4th quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company’s stock valued at $47,000 after buying an additional 1,976 shares during the period. Finally, Smithfield Trust Co boosted its stake in shares of Takeda Pharmaceutical by 76.9% in the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after buying an additional 1,490 shares during the last quarter. 9.17% of the stock is owned by institutional investors.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.